583 related articles for article (PubMed ID: 26618722)
1. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes.
Wang W; Wang X; Fujioka H; Hoppel C; Whone AL; Caldwell MA; Cullen PJ; Liu J; Zhu X
Nat Med; 2016 Jan; 22(1):54-63. PubMed ID: 26618722
[TBL] [Abstract][Full Text] [Related]
2. A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson's disease model.
Wang W; Ma X; Zhou L; Liu J; Zhu X
Hum Mol Genet; 2017 Feb; 26(4):781-789. PubMed ID: 28040727
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction.
Wang X; Petrie TG; Liu Y; Liu J; Fujioka H; Zhu X
J Neurochem; 2012 Jun; 121(5):830-9. PubMed ID: 22428580
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1.
Wang X; Yan MH; Fujioka H; Liu J; Wilson-Delfosse A; Chen SG; Perry G; Casadesus G; Zhu X
Hum Mol Genet; 2012 May; 21(9):1931-44. PubMed ID: 22228096
[TBL] [Abstract][Full Text] [Related]
5. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease.
Wang X; Su B; Liu W; He X; Gao Y; Castellani RJ; Perry G; Smith MA; Zhu X
Aging Cell; 2011 Oct; 10(5):807-23. PubMed ID: 21615675
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell.
Gan X; Huang S; Wu L; Wang Y; Hu G; Li G; Zhang H; Yu H; Swerdlow RH; Chen JX; Yan SS
Biochim Biophys Acta; 2014 Feb; 1842(2):220-31. PubMed ID: 24252614
[TBL] [Abstract][Full Text] [Related]
7. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.
Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X
Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227
[TBL] [Abstract][Full Text] [Related]
8. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function.
Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC
Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
Hanss Z; Larsen SB; Antony P; Mencke P; Massart F; Jarazo J; Schwamborn JC; Barbuti PA; Mellick GD; Krüger R
Mov Disord; 2021 Mar; 36(3):704-715. PubMed ID: 33142012
[TBL] [Abstract][Full Text] [Related]
10. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
[TBL] [Abstract][Full Text] [Related]
11. Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson's disease.
Zhao F; Wang W; Wang C; Siedlak SL; Fujioka H; Tang B; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1359-1370. PubMed ID: 28215578
[TBL] [Abstract][Full Text] [Related]
12. VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J; Moore DJ
Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
[TBL] [Abstract][Full Text] [Related]
14. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
15. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
Niu J; Yu M; Wang C; Xu Z
J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
[TBL] [Abstract][Full Text] [Related]
16. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits.
Zhou L; Wang W; Hoppel C; Liu J; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2791-2795. PubMed ID: 28765075
[TBL] [Abstract][Full Text] [Related]
18. Astrocytic dynamin-like protein 1 regulates neuronal protection against excitotoxicity in Parkinson disease.
Hoekstra JG; Cook TJ; Stewart T; Mattison H; Dreisbach MT; Hoffer ZS; Zhang J
Am J Pathol; 2015 Feb; 185(2):536-49. PubMed ID: 25482923
[TBL] [Abstract][Full Text] [Related]
19. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
[TBL] [Abstract][Full Text] [Related]
20. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
